42Z Stock Overview
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Revolution Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.60 |
| 52 Week High | US$37.20 |
| 52 Week Low | US$17.10 |
| Beta | 1.46 |
| 1 Month Change | 7.65% |
| 3 Month Change | 36.57% |
| 1 Year Change | 51.24% |
| 3 Year Change | 45.24% |
| 5 Year Change | n/a |
| Change since IPO | 21.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 42Z | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.7% | -1.2% | -1.0% |
| 1Y | 51.2% | -25.9% | 6.4% |
Return vs Industry: 42Z exceeded the German Biotechs industry which returned -24.6% over the past year.
Return vs Market: 42Z exceeded the German Market which returned 6.2% over the past year.
Price Volatility
| 42Z volatility | |
|---|---|
| 42Z Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 42Z's share price has been volatile over the past 3 months.
Volatility Over Time: 42Z's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 411 | Mark Goldsmith | www.revmed.com |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
Revolution Medicines, Inc. Fundamentals Summary
| 42Z fundamental statistics | |
|---|---|
| Market cap | €6.07b |
| Earnings (TTM) | -€447.95m |
| Revenue (TTM) | €4.22m |
1,378x
P/S Ratio-13.0x
P/E RatioIs 42Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 42Z income statement (TTM) | |
|---|---|
| Revenue | US$4.57m |
| Cost of Revenue | US$460.32m |
| Gross Profit | -US$455.75m |
| Other Expenses | US$28.52m |
| Earnings | -US$484.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.94 |
| Gross Margin | -9,981.43% |
| Net Profit Margin | -10,606.04% |
| Debt/Equity Ratio | 0% |
How did 42Z perform over the long term?
See historical performance and comparison